pentoxifylline has been researched along with Central Nervous System Diseases in 1 studies
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
Excerpt | Relevance | Reference |
---|---|---|
"Intrinsic estrogenicities of the selective estrogen receptor modulators (SERMs) toremifene 60 mg daily or 200 mg daily and tamoxifen 20 mg daily (TOR60, TOR200 and TAM20) were compared in a randomized clinical study in postmenopausal women with advanced breast cancer." | 9.10 | Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. ( Ellmén, J; Hakulinen, P; Hayes, DF; Partanen, A, 2003) |
"Intrinsic estrogenicities of the selective estrogen receptor modulators (SERMs) toremifene 60 mg daily or 200 mg daily and tamoxifen 20 mg daily (TOR60, TOR200 and TAM20) were compared in a randomized clinical study in postmenopausal women with advanced breast cancer." | 5.10 | Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. ( Ellmén, J; Hakulinen, P; Hayes, DF; Partanen, A, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ellmén, J | 1 |
Hakulinen, P | 1 |
Partanen, A | 1 |
Hayes, DF | 1 |
1 trial available for pentoxifylline and Central Nervous System Diseases
Article | Year |
---|---|
Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Antithrombin | 2003 |